Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistiCS 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.

Article  PubMed  Google Scholar 

Paydary K, Reizine N, Catenacci DVT. Immune-checkpoint inhibition in the treatment of gastro-esophageal cancer: a closer look at the emerging evidence. Cancers. 2021;13:5929.

Article  PubMed  PubMed Central  Google Scholar 

Shiravand Y, Khodadadi F, Kashani SMA, Hosseini-Fard SR, Hosseini S, Sadeghirad H, et al. Immune checkpoint inhibitors in cancer therapy. Curr Oncol. 2022;29:3044–60.

Article  PubMed  PubMed Central  Google Scholar 

• Zhou KI, Peterson B, Serritella A, Thomas J, Reizine N, Moya S, et al. Spatial and temporal heterogeneity of PD-L1 expression and tumor mutational burden in gastroesophageal adenocarcinoma at baseline diagnosis and after chemotherapy. Clin Cancer Res. 2020;26:6453–63. This reference is of importance because it discusses the intricate challenges and complexities encountered with PD-L1 immunohistochemistry assays, notably issues related to reproducibility, heterogeneity, and subjectivity, in the context of gastroesophageal cancer. By highlighting the consistent correlation between higher CPS scores and an increased likelihood of clinical benefit, while also navigating through the debate on the efficacy of PD-L1 as a standalone biomarker, the reference provides a critical foundation. It thereby aids in exploring and validating alternative or complementary biomarkers, ensuring informed and nuanced discussions and investigations in future immunotherapy response studies across gastroesophageal cancer trials.

Article  PubMed  PubMed Central  Google Scholar 

• Park R, Da Silva LL, Saeed A. Immunotherapy predictive molecular markers in advanced gastroesophageal cancer: MSI and beyond. Cancers. 2021;13:1715. This reference is of importance because it sheds light on the potential and early promise of various markers while emphasizing the necessity for their further prospective evaluations in the context of gastroesophageal cancer.

Article  PubMed  PubMed Central  Google Scholar 

•• Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. The Lancet. 2021;398:27–40. This reference is of outstanding importance because it is the phase III trial that demonstrated the superiority of first-line nivolumab plus chemotherapy to chemotherapy alone and it led to FDA approval.

Article  Google Scholar 

•• Sun J-M, Shen L, Shah MA, Enzinger P, Adenis A, Doi T, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. The Lancet. 2021;398:759–71. This reference is of outstanding importance because is the phase III trial that demonstrated the superiority of pembrolizumab plus chemotherapy to chemotherapy alone and it led to FDA approval.

Article  Google Scholar 

Shitara K, Ajani JA, Moehler M, Garrido M, Gallardo C, Shen L, et al. Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer. Nature. 2022;603:942–8.

Article  ADS  PubMed  PubMed Central  Google Scholar 

• Yap DWT, Leone AG, Wong NZH, Zhao JJ, Tey JCS, Sundar R, et al. Effectiveness of immune checkpoint inhibitors in patients with advanced esophageal squamous cell carcinoma: a meta-analysis including low PD-L1 subgroups. JAMA Oncol. 2023;9:215–24. This reference is of importance because it reveals insightful yet sobering findings regarding the efficacy of adding pembrolizumab to chemotherapy in low PD-L1–expressing gastric, esophageal, or GE cancers, specifically those with PD-L1 CPS 1 to 9. This metanalysis indicates no significant benefit of the addition of pembrolizumab in certain patient cohorts. Thus, it becomes a cornerstone for future research, guiding investigations and discussions toward understanding the varied impacts of immunotherapy across different PD-L1 expression levels and ensuring that subsequent trials and treatment strategies are sculpted with a more tailored approach.

Article  PubMed  Google Scholar 

Park Y, Koh J, Na HY, Kwak Y, Lee K-W, Ahn S-H, et al. PD-L1 testing in gastric cancer by the combined positive score of the 22C3 PharmDx and SP263 assay with clinically relevant cut-offs. Cancer Res Treat. 2020;52:661–70.

Article  PubMed  PubMed Central  Google Scholar 

Sajjadi E, Venetis K, Scatena C, Fusco N. Biomarkers for precision immunotherapy in the metastatic setting: hope or reality? Ecancermedicalscience. 2020;14:1150.

Article  PubMed  PubMed Central  Google Scholar 

Bang Y-J, Cutsem EV, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–97.

Article  PubMed  Google Scholar 

•• Janjigian YY, Kawazoe A, Yañez P, Li N, Lonardi S, Kolesnik O, et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature. 2021;600:727–30. This reference is of outstanding importance because it clearly demonstrated the benefits of adding pembrolizumab to trastuzumab and chemotherapy which led to FDA approval.

Article  ADS  PubMed  PubMed Central  Google Scholar 

KEYTRUDA® (pembrolizumab) plus trastuzumab and chemotherapy met primary endpoint of progression-free survival as first-line treatment in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma [Internet]. Merck.com. [cited 2023 Oct 2]. Available from: https://www.merck.com/news/keytruda-pembrolizumab-plus-trastuzumab-and-chemotherapy-met-primary-endpoint-of-progression-free-survival-as-first-line-treatment-in-patients-with-her2-positive-advanced-gastric-or-gastroesop/

•• Doki Y, Ajani JA, Kato K, Xu J, Wyrwicz L, Motoyama S, et al. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N Engl J Med. 2022;386:449–62. This reference is of outstanding importance because it is a phase III trial that underscored the pivotal role of nivolumab-based treatments, particularly in combination with chemotherapy, for advanced ESCC revealing a notable overall survival benefit compared to chemotherapy alone. Subgroup analyses illuminated that patients with a PD-L1 tumor proportion score (TPS) of ≥ 1% manifested pronounced survival advantages, thereby not only bolstering the FDA approval of Nivolumab but also emphasizing the significant impact of PD-L1 expression levels on treatment efficacy and survival outcomes in advanced ESCC.

Article  PubMed  Google Scholar 

Kang Y-K, Chen L-T, Ryu M-H, Oh D-Y, Oh SC, Chung HC, et al. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022;23:234–47.

Article  PubMed  Google Scholar 

•• Shitara K, Van Cutsem E, Bang Y-J, Fuchs C, Wyrwicz L, Lee K-W, et al. Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial. JAMA Oncol. 2020;6:1571–80. This reference is of outstanding importance because it is a phase III trial that illuminated the efficacy of pembrolizumab, especially within the MSI-H subgroup of advanced gastric cancer patients, showcasing a substantial survival benefit and reduced risk of death compared to chemotherapy alone. Particularly, it showed striking outcomes in patients with MSI-H tumors and a PD-L1 CPS of 1 or greater.

Article  PubMed  Google Scholar 

Kojima T, Shah MA, Muro K, Francois E, Adenis A, Hsu C-H, et al. Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer. J Clin Oncol. 2020;38:4138–48.

Article  PubMed  Google Scholar 

Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372:2509–20.

Article  PubMed  PubMed Central  Google Scholar 

•• Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord J-P, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair–deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2020;38:1–10. This reference is of outstanding importance because of spotlights the significance of tumor mutation burden (TMB) in immunotherapy response across varied tumor types. Despite its foundational role, the trial prompts critical inquiries regarding the universal applicability of the TMB cutoff of 10 mutations per megabase across diverse GI malignancies and underscores the necessity for further exploration and validation in steering management strategies, especially in gastro-esophageal cancers.

Article  PubMed  Google Scholar 

Samstein RM, Lee C-H, Shoushtari AN, Hellmann MD, Shen R, Janjigian YY, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet. 2019;51:202–6.

Article  PubMed  PubMed Central  Google Scholar 

Hsiehchen D, Hsieh A, Samstein RM, Lu T, Beg MS, Gerber DE, Wang T, Morris LGT, Zhu H. DNA repair gene mutations as predictors of immune checkpoint inhibitor response beyond tumor mutation burden. Cell reports medicine. 2020;1(3): 100034. https://doi.org/10.1016/j.xcrm.2020.100034.

Article  PubMed  PubMed Central  Google Scholar 

Nishikawa J, Iizasa H, Yoshiyama H, Shimokuri K, Kobayashi Y, Sasaki S, et al. Clinical importance of Epstein-Barr virus-associated gastric cancer. Cancers (Basel). 2018;10:167.

Article  PubMed  PubMed Central  Google Scholar 

Kim ST, Cristescu R, Bass AJ, Kim K-M, Odegaard JI, Kim K, et al. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat Med. 2018;24:1449–58.

Article  PubMed  Google Scholar 

Saeed A, Park R, Dai J, Al-Rajabi R, Kasi A, Baranda J, et al. Cabozantinib plus durvalumab in advanced gastroesophageal cancer and other gastrointestinal malignancies: phase Ib CAMILLA trial results. Cell Rep Med. 2023;4(2):100916. https://doi.org/10.1016/j.xcrm.2023.100916.

Article  PubMed  PubMed Central  Google Scholar 

Saeed A, Park R, Sun W. The integration of immune checkpoint inhibitors with VEGF targeted agents in advanced gastric and gastroesophageal adenocarcinoma: a review on the rationale and results of early phase trials. J Hematol Oncol. 2021;14:13.

Article  PubMed  PubMed Central  Google Scholar 

Cutsem EV, di Bartolomeo M, Smyth E, Chau I, Park H, Siena S, et al. Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study. Lancet Oncol. 2023;24:744–56.

Article  PubMed  Google Scholar 

Qi C, Gong J, Li J, Liu D, Qin Y, Ge S, et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. Nat Med. 2022;28:1189–98.

Lu Z, Chen H, Jiao X, Zhou W, Han W, Li S, et al. Prediction of immune checkpoint inhibition with immune oncology-related gene expression in gastrointestinal cancer using a machine learning classifier. J Immunother Cancer. 2020;8:e000631.

Article  PubMed  PubMed Central  Google Scholar